| Index | — | P/E | — | EPS (ttm) | -2.84 | Insider Own | 26.86% | Shs Outstand | 159.85M | Perf Week | 1.07% |
| Market Cap | 3.01B | Forward P/E | — | EPS next Y | -2.36 | Insider Trans | -0.04% | Shs Float | 149.71M | Perf Month | -5.70% |
| Enterprise Value | 2.33B | PEG | — | EPS next Q | -0.32 | Short Float | 10.34% | Perf Quarter | -21.97% | ||
| Income | -512.00M | P/S | — | EPS this Y | — | Short Ratio | 10.00 | Perf Half Y | 1.02% | ||
| Sales | 4.00M | P/B | 3.61 | EPS next Y | — | ROA | -44.17% | Short Interest | 15.48M | Perf YTD | 14.23% |
| Book/sh | 5.22 | P/C | 4.25 | EPS next 5Y | — | ROE | -55.27% | 52W High | 27.30 -30.92% | Perf Year | 15.14% |
| Cash/sh | 4.44 | P/FCF | — | EPS past 3/5Y | — | ROIC | -50.82% | 52W Low | 13.75 37.16% | Perf 3Y | -2.18% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | -61.04% | Volatility | 4.08% 4.09% | Perf 5Y | -60.35% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -15058.19% | ATR (14) | 0.79 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 8.32 | Sales Y/Y TTM | — | Profit Margin | -14191.20% | RSI (14) | 44.55 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 8.37 | EPS Q/Q | 5.56% | SMA20 | 0.66% | Beta | 1.05 | Target Price | 33.67 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | — | SMA50 | -8.09% | Rel Volume | 0.78 | Prev Close | 18.94 |
| Employees | 503 | LT Debt/Eq | 0.03 | Earnings | Nov 03 | SMA200 | -11.19% | Avg Volume | 1.58M | Price | 18.86 |
| IPO Date | Dec 08, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -32.54% 67.29% | Net Debt/EBITDA | — | Volume | 1,234,803 | Change | -0.42% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Robert W. Baird | $31 → $34 | |
| Aug-07-26 | Reiterated | UBS | Buy | $25 → $34 |
| Jul-23-26 | Reiterated | Morgan Stanley | Overweight | $35 → $36 |
| Jul-13-26 | Reiterated | Wedbush | Outperform | $20 → $26 |
| Jun-22-26 | Reiterated | Stifel Nicolaus | $37 → $41 | |
| May-22-26 | Reiterated | Deutsche Bank | $35 → $31 | |
| May-08-26 | Reiterated | Wedbush | Outperform | $30 → $23 |
| Mar-26-26 | Reiterated | Deutsche Bank | $26 → $35 | |
| Mar-02-26 | Reiterated | Jefferies | Buy | $45 → $40 |
| Jan-08-26 | Reiterated | Morgan Stanley | Overweight | $32 → $40 |
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4 | 0 | 0 | 331 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 6 | 11 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | -2 | -11 | 0 | 331 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 139 | 97 | 105 | 103 | — | — | — | — | — | |
| Research and Development | 401 | 419 | 396 | 424 | — | — | — | — | — | |
| Other Operating Expense | 0 | 28 | -14 | 0 | — | — | — | — | — | |
| Operating Income | -542 | -555 | -487 | -197 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 32 | 43 | 65 | 52 | — | — | — | — | — | |
| Net Income Before Taxes | -511 | -512 | -423 | -145 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -512 | -513 | -423 | -145 | — | — | — | — | — | |
| Net Income From Continuing Operations | -512 | -513 | -423 | -145 | — | — | — | — | — | |
| Net Income | -512 | -513 | -423 | -145 | — | — | — | — | — | |
| EPS (Recurring) | -2.84 | -2.97 | -2.57 | -1.06 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.84 | -2.97 | -2.57 | -1.06 | — | — | — | — | — | |
| EPS (Diluted) | -2.84 | -2.97 | -2.57 | -1.06 | — | — | — | — | — | |
| EBITDA | -499 | -498 | -493 | -128 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 881.70 | — | — | 8.88 | — | — | — | — | — | |
| Gross Margin | -50.00 | — | — | 100.00 | — | — | — | — | — | |
| Operating Margin | -13,550.00 | — | — | -59.52 | — | — | — | — | — | |
| Net Margin | -12,800.00 | — | — | -43.81 | — | — | — | — | — | |
| Shares Outstanding | 187 | 175 | 164 | 137 | — | — | — | — | — | |
| Market Capitalization | 3,527 | 2,889 | 3,342 | 2,940 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chin Peter Scott | Chief Medical Officer | Sep 04 '26 | Sale | 22.29 | 1,654 | 36,868 | 204,538 | Sep 09 |
| Thornberry Nancy | Director | Sep 02 '26 | Sale | 22.90 | 11,439 | 261,928 | 19,686 | Sep 04 |
| Schuth Alexander O. | COFO and Secretary | Sep 01 '26 | Sale | 23.44 | 2,768 | 64,882 | 278,995 | Sep 03 |
| Schuth Alexander O. | COFO and Secretary | Aug 11 '26 | Sale | 25.07 | 2,857 | 71,625 | 281,763 | Aug 13 |
| Schuth Alexander O. | COFO and Secretary | Jan 06 '26 | Sale | 16.50 | 17,218 | 284,097 | 282,828 | Jan 08 |
| Watts Ryan J. | President and CEO | Jan 06 '26 | Sale | 16.50 | 35,198 | 580,767 | 296,833 | Jan 08 |
| BAKER BROS. ADVISORS LP | Director | Dec 11 '25 | Buy | 0.01 | 2,285,714 | 22,857 | 25,996,310 | Dec 15 |
| Ho Carole | Chief Medical Officer | Aug 13 '25 | Sale | 14.64 | 806 | 11,800 | 216,585 | Aug 14 |
| Schuth Alexander O. | COFO and Secretary | Aug 12 '25 | Sale | 13.58 | 2,937 | 39,884 | 242,346 | Aug 14 |
| Ho Carole | Chief Medical Officer | Aug 12 '25 | Sale | 13.58 | 2,937 | 39,884 | 217,391 | Aug 14 |
| Ho Carole | Chief Medical Officer | Aug 05 '25 | Option Exercise | 0.68 | 44,655 | 30,365 | 220,328 | Aug 07 |
| Watts Ryan J. | President and CEO | Jul 09 '25 | Option Exercise | 1.05 | 495,282 | 520,792 | 748,353 | Jul 11 |
| Watts Ryan J. | President and CEO | Jul 09 '25 | Sale | 15.00 | 495,282 | 7,429,230 | 253,071 | Jul 11 |
| Ho Carole | Chief Medical Officer | Jan 07 '25 | Sale | 20.81 | 2,907 | 60,495 | 175,673 | Jan 08 |
| Schuth Alexander O. | COFO and Secretary | Jan 07 '25 | Sale | 20.81 | 2,907 | 60,495 | 244,308 | Jan 08 |